retatrutide triple agonist phase 2 obesity trial A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology retatrutide obesity triple hormone receptor
Pay in 4 interest-free payments of $7.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
























